DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases
This review is dedicated to the memory of Dr. Karen T. Liby, who passed away during the final editing of the manuscript. During her academic career, Karen made numerous extensive contributions to the pharmacology of Nrf2 activators, particularly to the preclinical development of the cyanoenone triterpenoids as multifunctional agents for prevention and treatment of chronic disease. Karen’s untimely passing is a huge loss for the Nrf2 community worldwide. Her kind personality and scientific rigour will be greatly missed., Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo., U.S. National Institutes of Health, R35 CA197222 (T.W.K.). PID- 2021-122766OB-1363 100 funded by MICIU/AEI/10.13039/ 501100011033 and by ERDF/EU (A.M.V.). National Science Centre grant OPUS (2021/43/B/NZ4/02130) (A.G-P). Swiss National Science Foundation grants 310 030_212 558 and IZCOZ0_205 415 (G.P.S.). Lundbeck Foundation (grant R366-2021-270 (A.B.). Medical Research Council UK [MR/T014644/1 (J.D.H., B.B., A.T.D-K) and MR/ W023806/1 (A T.D-K)], Biotechnology and Biological Sciences Research Council UK (BB/T508111/1 and BB/X00029X/1) (A.T.D-K), Tenovus Scotland (T22-08) (S.DN, A.T.D-K), and Reata Pharmaceuticals/Biogen (S.DN, A.T.D-K). Spanish Ministry of Science, Innovation and Universities (PID-2021-122766OB-100, PDC2021-121 421-I00, PDC2022-133 765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230) (A.C., A.I.R.). FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505) (E.C.). Spanish Ministry of Science (grant PID2021-123481OB-I00), Comunidad de Madrid (grant P2022/BMD-7230-CAM-22), and Fundación Teófilo Hernando” (R.L.). Romania Ministry of Research, Innovation and Digitization through the Nucleu grant PN23.16.02.01 (G.M.). Spanish Ministry of science innovation and universities Refs PDC2022-133 809-I00 and PID2021-125986OB-I00 and General Council for Research and Innovation of the Community of Madrid Ref. P2022/BMD-7230 to (M.G.L.). NIH National Cancer Institute: NIH F31 CA275239 (J.A.M). Cancer Foundation Finland, Sigrid Juselius Foundation (A.L.L.).